Similar companies
Income Statement (USD)
Q3 '24 | QoQ | |
---|---|---|
Gross Profit | -2.9M | 12.4% |
Cost of Revenue | 2.9M | 12.4% |
Operating expense | 14M | 6% |
Net Income | -13M | 7.2% |
EBITDA | -14M | 6.3% |
Balance Sheet (USD)
Q3 '24 | QoQ | |
---|---|---|
Total Assets | 69M | 6.6% |
Total Liabilities | 9.9M | 30.2% |
Total Equity | 59M | 10.9% |
Shares Outstanding | 75M | 3.9% |
Cash Flow (USD)
Q3 '24 | QoQ | |
---|---|---|
Cash from operations | -9.6M | 10.1% |
Cash from investing | 7.7M | 177% |
Cash from financing | 5M | 1.8% |
EPS
Financial Highlights for Trevi Therapeutics in Q3 '24
Gross Profit stood at -2.9M, marking a 12.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 2.9M, a -12.4% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 14M, showing a 6% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -13M, showing a -7.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -14M, showing a -6.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Trevi Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.